pan-european, rare disease
No One Left Behind
Researchers & developers of novel medicines for orphan diseases should witness their tremendous years-long efforts having meaningful impact on patients.
And patients should benefit from novel medicines for rare diseases regardless of where they live.
Download Our Latest Corporate Presentation
80%
European launches of orphan drugs fail to meet their commercial and revenue goals and do not reach patients in need.
Our Solution
We are on a mission to redefine the commercialization of orphan medicines to improve patient access across Europe and beyond. Derived from the word ‘Tanzanite’ – one of the rarest and most underappreciated gemstones on earth – Avanzanite was formed to capitalize on two primary objectives, one economic, and one humanitarian.
The economic goal is to offer end-to-end commercialization and distribution partnerships with research-based biopharmaceutical originators to unlock the full value of their orphan medicines in European markets. This is the unique expertise and core competency of our team following decades of operating experience navigating this area.
Equally important, our humanitarian goals stem from our commitment to enabling access to novel medicines for patients who suffer from orphan diseases regardless of where in Europe they live.
- Adam Plich, Founder & CEO
“It is our vision, at Avanzanite, to make lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla tortor magna, porttitor non consequat ornare, accumsan a turpis.”
Why global partners choose Avanzanite
Avanzanite is the go-to partner for rare disease companies seeking smart, risk-free entry into Europe. With deep expertise in pricing, market access, and pan-European commercialisation, we remove the barriers and distractions of launching in this complex region.
Our tailored, flexible deal structures and proven execution mean you can unlock value quickly – without the operational burden.
Backed by an expert team and a bold go-to-market model, we deliver access for patients and upside for partners.
Avanzanite in numbers
Employees by the
end of 2026
Approved orphan
medicines
Rare Disease Areas²
[2] Hematology, Nephrology, and Ophtalmology.
Countries EU¹, UK, CH
[1] 30 countries of the European Economic Area.
Aggregate years of experience
Every number represents a person, a family, and a life changed
Patient impact across Europe
Since becoming operational, Avanzanite has helped almost 200 patients across Europe access rare disease medicines that might otherwise not have reached them. From restoring sight, to supporting children’s growth, to improving quality of life for people living with lifelong conditions, patient impact sits at the heart of everything we do.
Our pan-European model allows us to reach patients not just in large markets, but across all 32 European countries — including those often overlooked.
Because rare diseases do not follow borders, and access should not either.
210
Patients supported
32
Countries reached across Europe
Avanzanites Champions League
Paragraph style 2 - Lorem Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Investors
